Pravastatin improves level of antithrombin Ⅲ in rats combined nephrotic syndrome with hypercoagulability / 中国临床药理学与治疗学

ABSTRACT

AIM: To investigate the anticoagulant effect of pravastatin and low molecular weight heparin (LMWH), as well as their combination, over time, in a rat model of experimental nephrotic syndrome. METHODS: Healthy SD male rats were chosen randomly to perform nephrotic syndrome models by single injection of adriamycin via tail vein, the matched normal control rats received single injection of equivalent 0.9% sodium chloride instead. After 14 days, the models were set up and randomized into model control group, pravastatin group (pravastatin 2 mg·kg-1·d-1 gavage once a day), LMWH group(LMWH 200 U·kg-1·d-1 intraperitoneal injection once a day) and combined treatment group(pravastatin 2 mg·kg-1·d-1 gavage+ LMWH 200 μ·kg-1·d-1 intraperitoneal injection), then all rats underwent measuring proteinuria every two weeks and fibrinogen, antithrombinⅢ(ATⅢ), D-dimer, platelet count, serum total protein and serum albumin after 4 weeks of treatment. RESULTS: The concentration of fibrinogen and D-dimer in model group was higher significantly than that in control group, and the level of ATⅢ was lower remarkably than that in control group, but platelet count had no obvious change; Compared with model group, pravastatin could increase the level of ATⅢ and decrease the concentration of D-dimer, but the concentration of fibrinogen and platelet count did not change obviously; LMWH and combined treatment could also decrease level of D-dimer, but had no great effects on ATⅢ, fibrinogen and platelet count; all treatment group had no obvious change of serum total protein and serum albumin. CONCLUSION: Adriamycin-induced nephrotic syndrome rat models have hypercoagulability and pravastatin can increase the level of ATⅢ.